hydroxychloroquine has been researched along with Vascular Diseases in 7 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Vascular Diseases: Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Hydroxychloroquine is an immune modulating drug that is considered safe in pregnancy." | 4.12 | Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro. ( Beard, S; Binder, N; Brownfoot, FC; Hannan, N; Harper, A; Kadife, E, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (42.86) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Kadife, E | 3 |
| Hannan, N | 3 |
| Harper, A | 3 |
| Binder, N | 3 |
| Beard, S | 3 |
| Brownfoot, FC | 3 |
| Hsu, CY | 1 |
| Lin, YS | 1 |
| Su, YJ | 1 |
| Lin, HF | 1 |
| Lin, MS | 1 |
| Syu, YJ | 1 |
| Cheng, TT | 1 |
| Yu, SF | 1 |
| Chen, JF | 1 |
| Chen, TH | 1 |
| Virdis, A | 1 |
| Tani, C | 1 |
| Duranti, E | 1 |
| Vagnani, S | 1 |
| Carli, L | 1 |
| Kühl, AA | 1 |
| Solini, A | 1 |
| Baldini, C | 1 |
| Talarico, R | 1 |
| Bombardieri, S | 1 |
| Taddei, S | 1 |
| Mosca, M | 1 |
| Lee, CK | 1 |
| Lee, TH | 1 |
| Lee, SH | 1 |
| Chung, IK | 1 |
| Park, SH | 1 |
| Kim, HS | 1 |
| Kim, SJ | 1 |
| RUBENSTEIN, M | 1 |
| WOLFF, SM | 1 |
| Harker, LA | 1 |
| Hirsh, J | 1 |
| Gent, M | 1 |
| Genton, E | 1 |
2 reviews available for hydroxychloroquine and Vascular Diseases
| Article | Year |
|---|---|
Critical evaluation of platelet-inhibiting drugs in thrombotic disease.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clo | 1975 |
Rheumatoid arthritis.
Topics: Antigen-Antibody Reactions; Arthritis, Juvenile; Arthritis, Rheumatoid; Aspirin; Biopsy; Chloroquine | 1973 |
1 trial available for hydroxychloroquine and Vascular Diseases
| Article | Year |
|---|---|
Critical evaluation of platelet-inhibiting drugs in thrombotic disease.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clo | 1975 |
5 other studies available for hydroxychloroquine and Vascular Diseases
| Article | Year |
|---|---|
Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Topics: Biomarkers; Endoglin; Endothelial Cells; Female; Humans; Hydroxychloroquine; Inflammation; Placenta; | 2022 |
Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Topics: Biomarkers; Endoglin; Endothelial Cells; Female; Humans; Hydroxychloroquine; Inflammation; Placenta; | 2022 |
Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Topics: Biomarkers; Endoglin; Endothelial Cells; Female; Humans; Hydroxychloroquine; Inflammation; Placenta; | 2022 |
Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Topics: Biomarkers; Endoglin; Endothelial Cells; Female; Humans; Hydroxychloroquine; Inflammation; Placenta; | 2022 |
Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Topics: Biomarkers; Endoglin; Endothelial Cells; Female; Humans; Hydroxychloroquine; Inflammation; Placenta; | 2022 |
Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Topics: Biomarkers; Endoglin; Endothelial Cells; Female; Humans; Hydroxychloroquine; Inflammation; Placenta; | 2022 |
Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Topics: Biomarkers; Endoglin; Endothelial Cells; Female; Humans; Hydroxychloroquine; Inflammation; Placenta; | 2022 |
Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Topics: Biomarkers; Endoglin; Endothelial Cells; Female; Humans; Hydroxychloroquine; Inflammation; Placenta; | 2022 |
Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Topics: Biomarkers; Endoglin; Endothelial Cells; Female; Humans; Hydroxychloroquine; Inflammation; Placenta; | 2022 |
Effect of long-term hydroxychloroquine on vascular events in patients with systemic lupus erythematosus: a database prospective cohort study.
Topics: Adolescent; Adult; Antirheumatic Agents; Databases, Factual; Female; Follow-Up Studies; Humans; Hydr | 2017 |
Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus.
Topics: Animals; Antioxidants; Antirheumatic Agents; Disease Models, Animal; Endothelium, Vascular; Female; | 2015 |
GI vasculitis associated with systemic lupus erythematosus.
Topics: Administration, Oral; Anti-Inflammatory Agents; Colon; Colonic Diseases; Colonoscopy; Diagnosis, Dif | 2010 |
PENILE NODULES AS A MAJOR MANIFESTATION OF SUBACUTE ANGIITIS.
Topics: Humans; Hydroxychloroquine; Infectious Mononucleosis; Male; Neuritis; Pathology; Penis; Prednisone; | 1964 |